Company intelligence / Profile preview

Neotope Biosciences

Ireland

Ownership: Private
Employees: ~80
Development stage: Other

Overview

Neotope Biosciences was an Irish-incorporated biotech focused on antibody therapies for misfolded proteins in neurodegenerative and amyloid diseases. It spun off from Elan in 2012, transferred many assets to Prothena, and its subsidiary Neotope Neuroscience (developer of PRX004 for ATTR amyloidosis) was acquired by Novo Nordisk in 2021.

Therapeutic areas: HematologyCardiovascularNeurologyRare Diseases
Modalities: Monoclonal antibody
Industry: Biotech

Partnerships

Elan Corporation (spin-off)Prothena Biosciences (assets transferred)Novo Nordisk (ATTR program acquisition)

Beyond the preview

Go deeper on Neotope Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neotope Biosciences.

Explore the full profile